Abstract: Amyloidosis is a multi-system disorder in which cardiac involvement often manifests with heart failure and/or arrhythmias. Recognition of cardiac amyloidosis is important as it is a potentially treatable cause of cardiomyopathy. While the approach to a case of suspected cardiac amyloidosis was discussed in a prior article, this one focuses on the management of its two main types (AL and ATTR). This is an area of active research with the advent of newer therapies such as RNA silencers and gene editing. We shall also discuss the management of heart failure and arrhythmias specific to amyloidosis.
© 2025 Journal of the Practice of Cardiovascular Sciences